These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 38978304)

  • 1. The immunomodulatory ballet of tumour-derived extracellular vesicles and neutrophils orchestrating the dynamic CD73/PD-L1 pathway in cancer.
    Rubenich DS; Domagalski JL; Gentil GFS; Eichberger J; Fiedler M; Weber F; Federlin M; Poeck H; Reichert TE; Ettl T; Bauer RJ; Braganhol E; Schulz D
    J Extracell Vesicles; 2024 Jul; 13(7):e12480. PubMed ID: 38978304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD73 in small extracellular vesicles derived from HNSCC defines tumour-associated immunosuppression mediated by macrophages in the microenvironment.
    Lu T; Zhang Z; Zhang J; Pan X; Zhu X; Wang X; Li Z; Ruan M; Li H; Chen W; Yan M
    J Extracell Vesicles; 2022 May; 11(5):e12218. PubMed ID: 35524455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of CD73 in predicting the response to immunotherapy in head and neck cancer patients.
    Botticelli A; Cirillo A; d'Amati G; Di Gioia C; Corsi A; Della Rocca C; Santini D; Carletti R; Pisano A; Polimeni A; De Vincentiis M; Valentini V; di Cristofano C; Romeo U; Cerbelli E; Messineo D; De Felice F; Leopizzi M; Cerbelli B
    Pathol Res Pract; 2024 Aug; 260():155415. PubMed ID: 38996615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific blockade CD73 alters the "exhausted" phenotype of T cells in head and neck squamous cell carcinoma.
    Deng WW; Li YC; Ma SR; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
    Int J Cancer; 2018 Sep; 143(6):1494-1504. PubMed ID: 29663369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD73 is associated with poor prognosis in HNSCC.
    Ren ZH; Lin CZ; Cao W; Yang R; Lu W; Liu ZQ; Chen YM; Yang X; Tian Z; Wang LZ; Li J; Wang X; Chen WT; Ji T; Zhang CP
    Oncotarget; 2016 Sep; 7(38):61690-61702. PubMed ID: 27557512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer.
    Qiao XW; Jiang J; Pang X; Huang MC; Tang YJ; Liang XH; Tang YL
    Front Immunol; 2020; 11():1721. PubMed ID: 33072064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The let-7 family of microRNAs suppresses immune evasion in head and neck squamous cell carcinoma by promoting PD-L1 degradation.
    Yu D; Liu X; Han G; Liu Y; Zhao X; Wang D; Bian X; Gu T; Wen L
    Cell Commun Signal; 2019 Dec; 17(1):173. PubMed ID: 31881947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MHC-I and PD-L1 Expression is Associated with Decreased Tumor Outgrowth and is Radiotherapy-inducible in the Murine Head and Neck Squamous Cell Carcinoma Model MOC1.
    Boreel DF; Sandker GGW; Ansems M; van den Bijgaart RJE; Peters JPW; Span PN; Adema GJ; Heskamp S; Bussink J
    Mol Imaging Biol; 2024 Oct; 26(5):835-846. PubMed ID: 39009951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment is mediated through matrix metalloproteinase-mediated proteolytic cleavage.
    Hira-Miyazawa M; Nakamura H; Hirai M; Kobayashi Y; Kitahara H; Bou-Gharios G; Kawashiri S
    Int J Oncol; 2018 Feb; 52(2):379-388. PubMed ID: 29345283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint inhibitor monotherapy is sufficient to promote microenvironmental normalization via the type I interferon pathway in PD-L1-expressing head and neck cancer.
    Jang JY; Lee BS; Huang M; Seo C; Choi JH; Shin YS; Woo HG; Kim CH
    Mol Oncol; 2024 Aug; 18(8):1923-1939. PubMed ID: 38511232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intratumoral CD73: An immune checkpoint shaping an inhibitory tumor microenvironment and implicating poor prognosis in Chinese melanoma cohorts.
    Gao Z; Wang L; Song Z; Ren M; Yang Y; Li J; Shen K; Li Y; Ding Y; Yang Y; Zhou Y; Wei C; Gu J
    Front Immunol; 2022; 13():954039. PubMed ID: 36131912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blockade of adenosine A2A receptor enhances CD8
    Ma SR; Deng WW; Liu JF; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
    Mol Cancer; 2017 Jun; 16(1):99. PubMed ID: 28592285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
    Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
    Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TIGIT/CD155 blockade enhances anti-PD-L1 therapy in head and neck squamous cell carcinoma by targeting myeloid-derived suppressor cells.
    Mao L; Xiao Y; Yang QC; Yang SC; Yang LL; Sun ZJ
    Oral Oncol; 2021 Oct; 121():105472. PubMed ID: 34333450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exosomal PD-L1 derived from head and neck squamous cell carcinoma promotes immune evasion by activating the positive feedback loop of activated regulatory T cell-M2 macrophage.
    Wei F; Fang R; Lyu K; Liao J; Long Y; Yang J; Wen W; Sun W
    Oral Oncol; 2023 Oct; 145():106532. PubMed ID: 37499326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomas.
    Sanchez-Canteli M; Granda-Díaz R; Del Rio-Ibisate N; Allonca E; López-Alvarez F; Agorreta J; Garmendia I; Montuenga LM; García-Pedrero JM; Rodrigo JP
    Cancer Immunol Immunother; 2020 Oct; 69(10):2089-2100. PubMed ID: 32448984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
    Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
    J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exosomes in HNSCC plasma as surrogate markers of tumour progression and immune competence.
    Theodoraki MN; Hoffmann TK; Jackson EK; Whiteside TL
    Clin Exp Immunol; 2018 Oct; 194(1):67-78. PubMed ID: 30229863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5'-Ectonucleotidase CD73/NT5E supports EGFR-mediated invasion of HPV-negative head and neck carcinoma cells.
    Shi E; Wu Z; Karaoglan BS; Schwenk-Zieger S; Kranz G; Abdul Razak N; Reichel CA; Canis M; Baumeister P; Zeidler R; Gires O
    J Biomed Sci; 2023 Aug; 30(1):72. PubMed ID: 37620936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The expression of immune checkpoint proteins PD-L1 and TIM3 in mouse and human head and neck squamous cell carcinoma.
    Elmusrati A; Wang CY
    Eur J Oral Sci; 2024 Oct; 132(5):e13010. PubMed ID: 39090710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.